Stephen Otieno Gwer1,2, Kennedy Odoyo Onyango3,2. 1. Department of Obstetrics and Gynecology Maseno University School of Medicine, Maseno, Kenya. 2. Afya Research Africa (ARA): a Joanna Briggs Institute Centre of Excellence. 3. Department of Physiology Maseno University School of Medicine, Maseno, Kenya.
Abstract
REVIEW QUESTION/ OBJECTIVE: What is the prevalence and incidence of congenital anomalies among babies born to women with sickle cell disease (SCD) and who have been exposed to hydroxyurea (HU) therapy at any time in their pregnancy?The objective of this review is to identify the proportion of babies born with congenital anomalies among babies born to mothers with SCD who have been exposed to HU therapy at any point during pregnancy and to describe the specific types of congenital anomalies encountered.
REVIEW QUESTION/ OBJECTIVE: What is the prevalence and incidence of congenital anomalies among babies born to women with sickle cell disease (SCD) and who have been exposed to hydroxyurea (HU) therapy at any time in their pregnancy?The objective of this review is to identify the proportion of babies born with congenital anomalies among babies born to mothers with SCD who have been exposed to HU therapy at any point during pregnancy and to describe the specific types of congenital anomalies encountered.